Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 618

1.

Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.

Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators.

Am J Epidemiol. 2006 Apr 1;163(7):589-99. Epub 2006 Feb 16.

PMID:
16484450
2.

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.

Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators.

Am J Epidemiol. 2005 Sep 1;162(5):404-14. Epub 2005 Jul 20.

PMID:
16033876
3.

Re: "combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial".

Willett WC, Manson JE, Grodstein F, Stampfer MJ, Colditz GA.

Am J Epidemiol. 2006 Jun 1;163(11):1067-8; author reply 1068-9. Epub 2006 Apr 26. No abstract available.

PMID:
16641306
4.
5.

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators.

J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.

PMID:
16174858
6.

Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial.

Yasmeen S, Romano PS, Pettinger M, Johnson SR, Hubbell FA, Lane DS, Hendrix SL.

Obstet Gynecol. 2006 Aug;108(2):410-9.

PMID:
16880313
7.

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ.

Ann Intern Med. 2000 Dec 19;133(12):933-41.

PMID:
11119394
9.

A comparative review of the risks and benefits of hormone replacement therapy regimens.

Warren MP.

Am J Obstet Gynecol. 2004 Apr;190(4):1141-67. Review.

PMID:
15118656
11.

The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practice.

Hendrix SL.

J Am Osteopath Assoc. 2003 Feb;103(2 Suppl 2):S3-5. No abstract available.

PMID:
12625631
12.

New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.

Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT.

Maturitas. 2005 Sep 16;52(1):1-10. Review.

13.

Postmenopausal hormone replacement therapy in the light of the women's health initiative trial.

van der Mooren MJ, Kenemans P.

Eur J Obstet Gynecol Reprod Biol. 2003 Apr 25;107(2):123-4. Review. No abstract available.

PMID:
12648855
14.

Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).

Robinson JG, Wallace R, Limacher M, Ren H, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG.

Am J Cardiol. 2008 Sep 15;102(6):693-9. doi: 10.1016/j.amjcard.2007.12.044. Epub 2008 Jul 2.

PMID:
18773990
15.

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE.

Am J Epidemiol. 2009 Jul 1;170(1):12-23. doi: 10.1093/aje/kwp115. Epub 2009 May 25.

16.

Perspectives on the Women's Health Initiative trial of hormone replacement therapy.

Grimes DA, Lobo RA.

Obstet Gynecol. 2002 Dec;100(6):1344-53. Review.

PMID:
12468183
17.

Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.

Harman SM, Naftolin F, Brinton EA, Judelson DR.

Ann N Y Acad Sci. 2005 Jun;1052:43-56.

PMID:
16024750
18.

Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.

Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, Allison M, Bonds DE, Masaki K, Caralis P, Kotchen JM; Women's Health Initiative Investigators.

Circulation. 2004 Feb 10;109(5):620-6.

19.

Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study.

Simon JA, Hunninghake DB, Agarwal SK, Lin F, Cauley JA, Ireland CC, Pickar JH.

Ann Intern Med. 2001 Oct 2;135(7):493-501.

PMID:
11578152
20.

The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program.

Hillman JJ, Zuckerman IH, Lee E.

J Womens Health (Larchmt). 2004 Nov;13(9):986-92.

PMID:
15665655

Supplemental Content

Support Center